Oct 24, 2022

October 24, 2022 Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X. The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant bacteria. Day Zero develops whole genome sequencing-based diagnostic technologies. The company designed them to identify both the species and the antibiotic resistance profile of a bacterial pathogen. It does so from a blood sample, within hours. This eliminates the need for a culture. “We greatly appreciate CARB-X’s continued support as we pioneer a new class of infectious disease diagnostics that leverage whole genome sequencing and machine learning to enable rapid identification of pathogens and their antibiotic resistance profile. Day Zero Diagnostics is determined to bend the curve on antibiotic resistance growth by enabling rapid and accurate diagnosis,” said Jong Lee, CEO of Day Zero Diagnostics. “This latest CARB-X award validates the tremendous progress our team of scientists and engineers have made in bringing these novel technologies to maturity and demonstrating the tremendous potential of genome sequencing technology in combating antibiotic resistance. CARB-X’s continued support now focuses on productizing these technologies so we can help fight the global threat of antibiotic resistance.” How Day Zero plans to use the funding Day Zero said that its option stage funding from CARB-X enables a transition into product development. Its ultimate goal remains the launch of an FDA-cleared and CE-marked in-vitro diagnostic instrument and cartridge system. The company is developing the system to provide a sample-to-answer solution. It incorporates the capabilities of the company’s novel technologies, including Blood2Bac. Blood2Bac is a proprietary sample preparation technology for ultra-high enrichment of bacterial DNA from clinical blood samples. Keynome, the Day Zero machine learning algorithm for species identification and resistance profiling, also features. Day Zero also intends to expand its MicrohmDB large-scale database. It combines pathogen genomic sequences with their known antibiotic resistance and susceptibility profiles. “We are pleased to support Day Zero Diagnostics’ development of its rapid infectious disease diagnostic technology,” said Erin Duffy, chief of research and development at CARB-X. “Day Zero’s whole genome sequencing and machine learning technology is a novel approach that could change the way infectious disease is diagnosed, help curb antibiotic resistance, and save lives.” A decade ago, medical device companies often turned to Europe to score initial regulatory approval for new products. Even though the U.S. is a larger market, many companies looked to Europe to win regulatory approval for their medtech innovation efforts. As a result, European patients received access to new therapies an average of two years earlier… […] Avail Medsystems is testing a third-party software integration that it plans to launch in the coming months. Avail executives said they hope it will be the first of many partnerships with medical technology developers of software or algorithms that could be useful in the operating room. Avail CEO Daniel Hawkins expects to launch the software… […] Medical devices ranging from in vitro diagnostic devices to wearable sensors/analyzers/aids are equipped with an ever-growing number of power management ICs, energy management units, and respective power supply circuits. To qualify for the use in medical devices, inductors must both meet the evolving demands as well as basic medical standards. Learn about the applications and… […] Patient-operated medical devices — such as those used in insulin delivery — require a focus on the usability requirements of the less-experienced end user. Philip Remedios, BlackHägen Design User-centered design is critical when developing new medical devices to support distance care. Medtech companies are now specifically designing devices for patient use outside of clinical settings. Digital… […] With healthtech AI investment booming, companies are seeking guidance on when and how to protect that work. Andrew (A.J.) Tibbetts, Greenberg Traurig Can you get intellectual property (IP) for artificial intelligence (AI)? Absolutely. Should you file a patent application? Maybe, but there are alternatives. Should you consider data options? Yes. Is there a standard strategy… […] Medical device usability research and human factors engineering starts with device users, the use environment and user interfaces. Gregory Montalbano, MIDI Medical Product Development Designing a medical device is not a lighthearted or straightforward task. Every design choice during the development process can influence how the device is used, whether it is effective and if… […] Confluent Medical Technologies announced today that it appointed Matthew Eckl as its new chief financial officer (CFO). The Scottsdale, Arizona-based company made Eckl’s appointment effective today. His responsibilities include global financial strategy and financial operations. The company intends for Eckl to lead its accounting, financial planning and analysis, legal and information technology teams. “We are… […] The future of medical device design is in our hands. Here’s what it’ll take to get there. Tony Kaufman, 3M It’s an exciting and challenging time in medical device history. From tracking vital signs to enabling more informed conversations with health professionals, device users can take control of their health in new and powerful ways.… […] Researchers at the Massachusetts Institute of Technology (MIT) developed an unsupervised physical rehabilitation system. MuscleRehab came from researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Massachusetts General Hospital (MGH). Together, they combined three ingredients: motion tracking, imaging and virtual reality (VR). The motion tracking captures motion activity. The electrical impedance tomography (EIT)… […] Private equity firm Vance Street Capital said today that it has purchased Mountain Manufacturing Technologies. Terms of the deal were not disclosed. Lino Lakes, Minnesota-based Mountain Manufacturing Technologies is a wire and metal tube supplier for the interventional and advanced surgical markets. Los Angeles-based Vance Street said the acquisition would complement another company in its… […]